Inflammation in atherosclerosis, not yet time for a paradigm shift?

Current Opinion in Lipidology

Volumn 14, Issue 3, 2003, Pages 325-328

  Cullen, Paul ^a,b,c   Lorkowski, Stefan ^a   Schulte, Helmut ^a   Seedorf, Udo ^a   Assmann, Gerd ^a  

^a Inst fur Arterioskleroseforschung   (Germany)

^b Ogham GmbH   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN;

ALGORITHM; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CATALYSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; ENDARTERITIS; ENDOTHELIUM CELL; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; MACROPHAGE; MEDICAL INFORMATION; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN BINDING; REDUCTION; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HEAT-SHOCK PROTEINS; HUMANS; INFLAMMATION; NF-KAPPA B;

EID: 0037495063     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200306000-00012     Document Type: Review

References (18)

1. Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin: Verlag von August Hirschwald; 1858.
2. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565. An important study because of its prospective design. A previous report on this population had been based on a case-control analysis with 3 years of follow-up.
3. • •] into perspective.
4. Wilson PWF, d'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factors categories. Circulation 1998; 97:1837-1847.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
6. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139:272-281.
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
8. Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-1332. Interesting paper localizing section of cholesterol synthesis pathway involved in regulation of anti-inflammatory response.
9. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 2003; 108:539-547.
10. Kim SI, Kim HJ, Han DC, Lee HB. Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronection expression. Kidney Int Suppl 2000; 77:S88-S92.
11. Yang BC, Wang YS, Liu HS, Lin SJ. Ras signaling is involved in the expression of Fas-L in glioma. Lab Invest 2000; 80:529-537.
12. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-291.
13. Hansson GK. Vaccination against atherosclerosis: science or fiction? Circulation 2002; 106:1599-1601.
14. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22:1547-1559.
15. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (ldl) receptor-deficient rabbits with homologous malondialdehyde-modified ldl reduces atherogenesis. Proc Natl Acad Sci U S A 1995; 92:821-825.
16. Maron R, Sukhova G, Faria AM, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106:1708-1715.
17. Blake GJ, Ridker PM. C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002; 22:1512-1513.
18. The Brigham and Women's Hospital Inc. US patent number 6,040,147 (March 21, 2000). Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents for the prevention and treatment of atherosclerotic disease. Inventors: Ridker P, Hennekens CH.